Entera Bio (NASDAQ:ENTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a research note issued to investors on Monday morning, Benzinga reports. The firm currently has a $10.00 target price on the stock.

Entera Bio Stock Up 1.1 %

Shares of NASDAQ:ENTX opened at $1.78 on Monday. The company’s 50 day moving average price is $1.79 and its two-hundred day moving average price is $1.96. Entera Bio has a 12-month low of $0.52 and a 12-month high of $3.35. The firm has a market cap of $63.70 million, a PE ratio of -6.36 and a beta of 1.57.

Entera Bio (NASDAQ:ENTX) last announced its earnings results on Friday, August 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06). The business had revenue of $0.06 million for the quarter. On average, research analysts expect that Entera Bio will post -0.23 EPS for the current year.

Institutional Trading of Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC purchased a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 22,040 shares of the company’s stock, valued at approximately $37,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.